A phase I study of RMC-035 to evaluate safety in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2018
At a glance
- Drugs RMC 035 (Primary)
- Indications Acute kidney injury; Preeclampsia; Radiation injuries
- Focus Adverse reactions
- 09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has granted permission to start this Phase I trial.
- 01 Nov 2018 According to an A1M Pharma AB media release, this trial is expected to begin in the first quarter of 2019.This study is estimated to take approximately six months to complete.
- 20 Sep 2018 According to an A1M Pharma AB media release, a new application has been submitted to the Swedish Medicines Agency , and data from the new production has been included in a renewed application. This study will be conducted together with the contract research company CTC in Uppsala.